Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis H A Capell, M Brzeski Most rheumatologists use slow acting antirheumatic drugs (SAARDs) for treatment of rheumatoid arthritis (RA). This review looks at the perils and pitfalls associated with the introduction of new compounds in RA, the attempts that have been made to optimise available drugs, and the dilemmas of early and combination treatment. Finally, a brief mention is made of immunotherapy, which seems unlikely to provide a panacea in the near future.
Clearly, earlier terminology, such as 'remission inducing drugs', is not justified by the performance of these agents, and even 'disease modifying antirheumatic drug' implies a promise of a more fundamental effect on RA than is commonly produced. An acceptable alternative is 'second line drug', which encompasses the concept of another tier of treatment for generalised disease inadequately restrained by analgesia and non-steroidal antiinflammatory drugs. The implication of 'stepping up' the power of a drug treatment may also help patients to accept the risks of side effects of these drugs. The aim of complete disease remission, and the documented slow onset of action, sets these drugs apart from all other types of treatment in RA.
In this review the term slow acting antirheumatic drugs will be used to include antimalarial drugs, gold, penicillamine, sulphasalazine, and selected cytotoxic agents.
High drop out rates are a feature of these drugs, and as sustained intervention over many years is often necessary in the management of RA, rheumatologists may be forgiven for a feeling of frustration with the relative lack of progress in therapeutic options over the past 10 years. ' 3 Of those patients who do improve and experience no side effects, some will discontinue the drug owing to later loss of effect ('escape from control'). Compared with other SAARDs, injectable gold is generally regarded as producing fewest withdrawals for lack of effect (it is not clear how much this is due to the complete compliance obtained by intramuscular administration) and most withdrawals for side effects,4 though not all studies confirm this.5
Evaluation of new compounds Overall, a large proportion of patients do not continue to receive any given drug for more than one year,3 so the search has continued for other, improved compounds. The difficulties of assessing disease activity and response to treatment are relevant to the search for new drugs but beyond the scope of this paper. Likewise, the possibly declining severity of RA during this century, and any effect of routine use of low dose steroids (hotly debated and currently being assessed), may carry implications for future management.
Assessment of new compounds in RA has long been bedevilled by the inability to elucidate mechanisms whereby these drugs exert their effect. While much remains to be explained about non-steroidal anti-inflammatory drugs, the arachidonic acid pathway and the effects of these agents on cyclo-oxygenase are well understood. By contrast, virtually all available second line agents for RA were discovered serendipitously and even the choice of the designer drug sulphasalazine was based on a false premise.
Failures
The track record of new compounds which have failed to reach fruition makes depressing reading: levamisole was effective but unacceptably toxic'; fenclofenac disappeared in infancy because of rashes despite early promise7; clozic followed a similar fate; benoxaprofen led to 24 The role of thiol groups may be critical-the restoration of impaired redox homeostasis across cell membranes25-yet their presence in a compound is neither a guarantee of second line activity26 nor a prerequisite, as sulphasalazine demonstrates.
Cyclosporin A still has promise. A potent immunomodulator, it undoubtedly exerts an effect in RA at the high dose of 6-10 mg/kg daily,27 28 but its usefulness in the long term is limited by fears of (irreversible?) nephrotoxicity. Lower doses (mean 3-8 mg/kg daily) are therapeutic but still toxic, and not all patients with cyclosporin induced nephropathy revert to baseline renal function after drug withdrawal. 29 There are indirect suggestions that prostaglandin analogues (misoprostol) may ameliorate this problem if given in addition to cyclosporin. 30 Although potentially convenient for those with peptic ulceration induced by non-steroidal antiinflammatory drugs, the data sheet would currently exclude women of child bearing years, unless using adequate contraception and diarrhoea might lead to withdrawal in a significant proportion of patients if full dose were used.
Successes
What has proved successful in the 1980s? The list is depressingly short, but nevertheless clinically valuable. Auranofm is in essence a reformulation of a known effective drug, sulphasalazine is a resurrection of a compound previously known to be effective, and methotrexate has moved sideways from dermatology. Proponents of delay rightly point out that as RA may remit or become less severe in many patients in the first year a large group of patients will be treated with SAARDs unnecessarily, with the allied cost in time, money, and exposure to potential side effects. It is not known whether SAARD treatment started within one or two months of disease onset, or before erosions have occurred, would confer any further benefit, or even arrest the process in its tracks. Conversely, the best chance of preserving good function and preventing disability, rather than responding to it, may lie in vigorous early treatment where there is a possibility of inducing remission before the disease has become entrenched. One risk of this approach is that as patients work their way through the SAARDs, cytotoxic drugs may be invoked earlier in the disease, and thus at an earlier age of the patient, an important point when considering possible late neoplasia. We need the ability reliably to identify, at an early stage, those patients with a poor prognosis. General features-for example, seropositivity, which predict more severe disease are not sufficiently specific to help in the individual case.
One important measure of disease activity is progression of erosions and joint space loss as seen on plain radiographs. Comparison of serial radiographs is fraught with difficulties, and most studies have concentrated on hands, though not all joints suffer radiological worsening concurrently or at the same rate. 6 
